US Edition
News from oncnursingnews.com
We’ve assigned a media bias rating of unknown to oncnursingnews.com. You can read more about our methodology here.
If you want to know if oncnursingnews.com is credible or reliable, look no further. We rank oncnursingnews.com as Unknown factuality. Find out more about our methodology here.
Information about oncnursingnews.com
Where is oncnursingnews.com located?oncnursingnews.com's WebsiteMedia Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top oncnursingnews.com News
Amgen · United States/PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today that the U.S. Food and Drug Administration (FDA) has granted full approval to IMDELLTRA® (tarlatamab-dlle)...See the Story
FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
60% Center coverage: 5 sources
Cancer · United StatesFDA approves AstraZeneca's Imfinzi plus FLOT for early gastric and GEJ cancers after Phase 3 data show strong event-free and overall survival benefits.See the Story
AstraZeneca Wins FDA Nod For Imfinzi Combination Regimen In Tough-To-Treat Stomach Cancers - AstraZeneca (NASDAQ:AZN)
100% Center coverage: 1 sources
FDA · United StatesThe FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph in combination with enfortumab vedotin-ejfv for certain adults with muscle invasive bladder cancer.The indication applies to adults who are ineligible for cisplatin, and for use as neoadjuvant treatment followed by adjuvant treatment after cystectomy.See the Story
FDA Approves Keytruda Plus Padcev for Muscle Invasive Bladder Cancer
100% Center coverage: 1 sources
